Information Provided By:
Fly News Breaks for May 18, 2017
AGIO
May 18, 2017 | 07:58 EDT
SunTrust analyst Yatin Suneja says that the 9.3 months median overall survival rate for patients taking Agios' Idhifa in a Phase I trial was "favorable" and impressive. Suneja continues to expect the drug to be approved. The analyst keeps a $68 price target and a Buy rating on the stock.
News For AGIO From the Last 2 Days
There are no results for your query AGIO